HSPA5 and acute myeloid leukemia: While GRP78-CAR T cell treated mice had a significant increase in overall survival (OS) in comparison to mice that had received control- or GRP78.ΔCAR T cells (p < 0.0001), AML eventually progressed (Fig. 6c, Supplementary Fig. 8).